Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt

Rheumatol Int. 2020 Oct;40(10):1599-1611. doi: 10.1007/s00296-020-04655-9. Epub 2020 Jul 24.

Abstract

The aim of this work is to trace how rheumatologists all over Egypt are approaching the COVID-19 pandemic and what changes it has brought about in the patients' care with special attention to its effect on vulnerable rheumatic disease (RD) patients. This survey further aims to help inform the rheumatology community about the changes in practice during the COVID-19 pandemic. The survey included 26 questions distributed to University staff members across Egypt members of the Egyptian College of Rheumatology (ECR). It takes 5-10 min to fill out. The practice setting of participating rheumatologists included University Teaching Hospitals that are the main rheumatology and clinical immunology service providers for adults and children RD patients. There was an overall agreement across the country in the responses to the survey that took a median time of 7 min to fill in. Potential changes in rheumatology outpatient practice by staff members evolved since the COVID-19 pandemic. None of the university rheumatology staff members has prescribed chloroquine or HCQ to prevent or treat COVID-19 in a non-hospitalized patient who was not previously on it. Twenty-three recommended decrease/avoid NSAIDs if the RD patient had confirmed COVID-19 or symptoms. There is an agreement to the key emerging frontline role of rheumatologists in treating COVID-19. During the pandemic, RD cases requiring admission were dealt with by several modified strategies. The overall agreement among the different university rheumatology departments during such critical situation has provoked the ECR to consider providing provisional guidelines for dealing with RD patients during this global catastrophe.

Keywords: COVID-19 pandemic; Egyptian college of rheumatology; Practice; Rheumatologists; Survey.

MeSH terms

  • Ambulatory Care / statistics & numerical data
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antirheumatic Agents / supply & distribution
  • Antirheumatic Agents / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control
  • Deprescriptions
  • Egypt / epidemiology
  • Humans
  • Hydroxychloroquine / supply & distribution
  • Hydroxychloroquine / therapeutic use
  • Pandemics / prevention & control
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Rheumatic Diseases / drug therapy*
  • Rheumatologists / statistics & numerical data*
  • Rheumatology
  • SARS-CoV-2
  • Surveys and Questionnaires

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Hydroxychloroquine